Cross-Reactive T Cells Offer Hope for Broad Vaccines Against Measles and Nipah Virus
Researchers at the La Jolla Institute for Immunology have discovered that cross-reactive T cells could be key in developing broad vaccines or treatments for paramyxoviruses, including measles and Nipah virus. The study, led by Alessandro Sette, PhD, mapped human CD4+ T cell epitopes across these viruses, revealing conserved regions that could trigger immune responses against multiple paramyxovirus species. This finding suggests that instead of targeting individual viruses, vaccines could be designed to activate these cross-reactive T cells, offering protection against a wider range of viruses within the family. The research highlights the potential for new vaccine strategies that leverage existing population immunity. 
